Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Equity-to-Asset : 0.82 (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Taro Pharmaceutical Industries's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,779.1 Mil. Taro Pharmaceutical Industries's Total Assets for the quarter that ended in Dec. 2023 was $2,163.2 Mil. Therefore, Taro Pharmaceutical Industries's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.82.

The historical rank and industry rank for Taro Pharmaceutical Industries's Equity-to-Asset or its related term are showing as below:

TARO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.69 Med: 0.85 Max: 0.92
Current: 0.82

During the past 13 years, the highest Equity to Asset Ratio of Taro Pharmaceutical Industries was 0.92. The lowest was 0.69. And the median was 0.85.

TARO's Equity-to-Asset is ranked better than
84.65% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs TARO: 0.82

Taro Pharmaceutical Industries Equity-to-Asset Historical Data

The historical data trend for Taro Pharmaceutical Industries's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Equity-to-Asset Chart

Taro Pharmaceutical Industries Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Equity-to-Asset

Get a 7-Day Free Trial

0.89

0.90

0.71

0.79

0.81

Taro Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															-	0.81	0.81	0.83	0.82

Competitive Comparison of Taro Pharmaceutical Industries's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taro Pharmaceutical Industries's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Equity-to-Asset falls into.

Taro Pharmaceutical Industries Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Taro Pharmaceutical Industries's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1730.859	/	2135.513
	=	0.81

Taro Pharmaceutical Industries's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1779.093	/	2163.179
	=	0.82

Taro Pharmaceutical Industries (NYSE:TARO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Taro Pharmaceutical Industries Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

TAL:Germany

Address

14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761

Website

https://www.taro.com

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Executives

Sun Pharma Global Inc	10 percent owner
Sun Pharmaceutical Industries Ltd	10 percent owner, other: Affiliated Party	17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd.	10 percent owner	KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc	10 percent owner	FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403